

**Recommendations of the SEC (Endocrinology & Metabolism) made in its 81<sup>st</sup> meeting held on 24.11.2021 & 25.11.21 at CDSCO HQ New Delhi:**

| S.No                       | File Name & Drug Name, Strength                    | Firm Name                       | Recommendations  |
|----------------------------|--|---------------------------------|--|
| <b>New Drugs Division</b>  |  |                                 |  |
| 1.                         | ND/MA/21/000169<br>Imeglimin 500 mg/1000mg tablets | M/s. Exemed                     | <p>The firm presented their proposal of manufacturing and marketing of the drug Imeglimin 500 mg and 1000 mg tablet along Phase III clinical trial study protocol and BA/BE study protocol before committee.</p> <p>After detailed deliberation, the committee recommended that the firm should submit bioequivalence study results before the committee for further consideration of the proposed Phase III clinical trial of the drug Imeglimin 500 mg and 1000 mg tablet.</p>   |
| 2.                         | ND/MP/20/000148<br>Trelagliptine Tablet            | M/s. Hetero Labs                | <p>In light of earlier recommendation dated 16-12-2020, the firm presented amended Phase III clinical trial protocol before the committee.</p> <p>After detailed deliberation, the committee recommended that the firm should submit bioequivalence study results before the committee for further consideration of the proposed Phase III clinical trial of the drug Trelagliptine tablet.</p>  |
| 3.                         | ND/MA/21/000157<br>Imeglimin 500mg and 1000mg      | M/s. Synokem                    | <p>In light of earlier recommendation dated 26-10-2021, the firm presented detailed non clinical and clinical data of safety and efficacy of the drug and justification for the proposed clinical trial with the drug including 1000mg.</p> <p>After detailed deliberation, the committee recommended that the firm should submit bioequivalence study results before the committee for further consideration of the proposed Phase III clinical trial of the drug Imeglimin 500mg and 1000mg. The committee also recommended to submit the data related to the drug product formulation as per the requirements of NDCT rules 2019.</p> |
| <b>Biological Division</b> |  |                                 |  |
| 4.                         | BIO/CT21/21/000104<br>Teriparatide                 | M/s. Enzene Biosciences Limited | <p>The firm presented Phase IV clinical trial proposal before the committee.</p> <p>After detailed deliberation the committee</p>  |

| S.No                | File Name & Drug Name, Strength  | Firm Name                     | Recommendations  |
|---------------------|--|-------------------------------|--|
|                     |  |                               | <p>recommended for grant of permission for conduct of Phase IV clinical trial subject to following conditions –</p> <p>(1) Estimation of Bone markers should be included and evaluated at 3<sup>rd</sup> and 6<sup>th</sup> months.</p> <p>(2) Evaluation of BMD should be uniform across all the centers preferably using the same make and model of the equipment.</p> <p>(3) Sample size should be determined to have atleast 200 evaluable patients.</p> <p>Accordingly, the firm should submit revised protocol to CDSCO for further necessary action.</p>  |
| <b>SND Division</b> |  |                               |  |
| 5.                  | SND/MA/21/000453<br>Cholecalciferol<br>Sachets 60,000 IU                               | M/s. Akums<br>Pharmaceuticals | The firm didn't turn up for presentation.  |
| 6.                  | SND/CT/21/000042<br>Nano Carrier<br>Entrapped Vitamin<br>D3 Oral Dispersion<br>60000IU | M/s. Pulse Pharma             | <p>In light of the earlier SEC recommendation dated 24/08/2021, the firm presented revised clinical trial protocol.</p> <p>After detailed deliberation, the committee recommended for grant of permission for conduct of the clinical trial as per the protocol presented subject to the conditions that</p> <ol style="list-style-type: none"> <li>1. The reference product used in the trial should be approved by the CDSCO.</li> <li>2. PK assessment should be carried out for cholecalciferol and 25-Hydroxy cholecalciferol.</li> </ol> <p>Accordingly, the firm should submit the revised protocol to CDSCO prior to initiation of the clinical trial.</p> |
| 7.                  | SND/MA/21/000302<br>Nano Carrier<br>Entrapped Vitamin<br>D3 Oral Dispersion<br>400IU   | M/s. Pulse Pharma             | <p>In light of the earlier SEC meeting recommendation dated 24/08/2021, the firm presented justification for clinical trial waiver.</p> <p>After detailed deliberation, the committee recommended that the decision on the clinical trial waiver may be considered based on the outcome of the clinical trial conducted with Nano Carrier Entrapped Vitamin D3 Oral Dispersion 60000IU.</p>  |
| <b>FDC Division</b> |  |                               |  |

| S.No | File Name & Drug Name, Strength  | Firm Name                            | Recommendations  |
|------|--|--------------------------------------|--|
| 8.   | FDC/MA/20/000235<br>Vildagliptin SR + Metformin<br>(SR)(50mg/50mg/100mg/100mg + 500mg/1000mg/500mg/1000mg) tablets                       | M/s. Pure & Cure Healthcare Pvt. Ltd | <p>The firm presented their proposal along with BE study protocol as well as two Phase III CT study protocols.</p> <p>After detailed deliberation, the committee recommended for grant of permission to conduct the BE study and the first proposed Phase III CT study with FDC of Vildagliptin SR + Metformin (SR) (100mg/100mg + 500mg/1000mg). With regard to second Phase III CT study with FDC of Vildagliptin SR + Metformin (SR) (50mg/50mg + 500mg/1000mg), the committee opined that:</p> <ol style="list-style-type: none"> <li>1. Appropriate comparator should be taken.</li> <li>2. HbA1C level should be between 7.5 to 10.</li> </ol> <p>The firm should submit revised second Phase III CT protocol for review by the committee.</p>   |
| 9.   | FDC/MA/21/000249<br>Sitagliptin Phosphate Monohydrate<br>50mg/100mg+Dapagliflozin Propanediol monohydrate<br>5mg/10mg film coated tablet | M/s. Pinnacle Life Science Pvt. Ltd. | <p>The firm presented their proposal along with BE study protocol as well as Phase III CT study protocol.</p> <p>After detailed deliberation, the committee recommended that:</p> <ol style="list-style-type: none"> <li>1. Active treatment duration should be of minimum 16 weeks.</li> <li>2. The firm should conduct a comparative randomized clinical trial with appropriate comparator.</li> <li>3. The inclusion criteria should be elaborated.</li> <li>4. Study sites should be distributed geographically &amp; some Government sites should also be included.</li> </ol> <p>In view of above committee recommended that the firm should submit revised Phase III CT study protocol for further review by the committee.</p> <p>The committee also recommended for grant of permission for conducting the proposed BE study.</p> |
| 10.  | FDC/CT21/FF/2021/28649<br>Sitagliptin phosphate monohydrate 50mg/10  | M/s. Exemed Pharmaceuticals          | <p>The firm presented their proposal along with phase III CT protocol before the committee and along with justification for BE study waiver.</p>   |

| S.No                | File Name & Drug Name, Strength  | Firm Name                         | Recommendations   |
|---------------------|--|-----------------------------------|---|
|                     | 0mg+Dapagliflozin propanediol monohydrate 5mg/10mg tablets   |                                   | <p>The committee noted that the firm has proposed clinical trial for the higher strength only.</p> <p>After detailed deliberation, the committee recommended for grant of permission for conducting the proposed phase III clinical trial.</p> <p>As regard to the proposed lower strength, committee recommended that decision w.r.t. approval of the proposed lower strength will be taken later based on phase III study results.</p>  |
| 11.                 | FDC/MA/21/000259<br>Metformin Hydrochloride IP<br>500mg/500mg/1000mg/1000mg+<br>Glimepiride IP<br>1mg/2mg/1mg/2mg+<br>Dapagliflozin propanediol monohydrate<br>5mg/5mg/5mg/5mg tablets | M/s. Sun Pharma Laboratories Ltd. | <p>The firm presented their proposal along with BE study protocol as well as Phase III CT study protocol.</p> <p>After detailed deliberation, the committee recommended for grant of permission for conducting the proposed BE/CT studies.</p>  |
| <b>GCT Division</b> |  |                                   |   |
| 12.                 | CT/51/16<br>Online Submission (11876)<br>Dulaglutide   | M/s. Eli Lilly                    | <p>The firm presented protocol amendment H9X-MC_GBGC(e) dated 15-OCT-2021 before the committee.</p> <p>After detailed deliberation, the committee did not recommend for approval of the proposed protocol amendment. The committee asked the firm to present proper justification with rationale for change in the primary and secondary objectives, efficacy measures etc from Wk 26 to Wk52, when the double blind phase (Wk26) of the study and primary database locks at Wk 26 is already over.</p>   |
| 13.                 | CT/90/21<br>Online Submission (27335)<br>IcoSema (700 U/ml + 2mg/ml)   | M/s. Novo-Nordisk                 | <p>The firm presented the proposed phase 3a study protocol no. NN1535-4593, Ver. 2.0 dated 01JUL2021 with IP-IcoSema (Insuline Icodec 700U/ml + Semaglutide 2.0mg/ml) before the Committee.</p> <p><b>Risk-Benefit Assessment:</b> Insulin icodec is currently in development for treatment of diabetes mellitus and Semaglutide has already been approved for the treatment of T2DM. In both clinical and non-clinical trials, insulin icodec has shown to have a long and stable PK and PD profile,</p> |

| S.No | File Name & Drug Name, Strength                         | Firm Name             | Recommendations  |
|------|---|-----------------------|--|
|      |   |                       | <p>supporting a once weekly treatment. The treatment adherence and quality of life are expected to increase by introducing a once weekly basal insulin treatment.</p> <p><b>Innovation Vs Existing Therapy:</b> This study is designed to investigate the efficacy and safety of once weekly IcoSema, which is a combination product of insulin icodec and semaglutide. IcoSema will be compared to daily insulin glargine 100 units/ml combined with insulin aspart, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin.</p> <p><b>Unmet Need:</b> Maintenance of tight glycaemic control is important to reduce the risk of long-term complications associated with the disease. Hence, there is a need for a new insulin treatment with simple regimen, less injections, resulting in better convenience and patient's adherence, therefore it may overcome the barriers of insulin intensification in T2D patients, and improve the glycaemic control of T2D patients in the country.</p> <p>After detailed deliberation, the Committee recommended for the conduct of the proposed clinical trial with the following conditions:</p> <ol style="list-style-type: none"> <li>1) Trial subjects will be of age equal to or more than 18 years at the time of signing ICF. However, if the subject age is equal to or more than 60 years and having HbA1C more than or equal to 7.5%, should only be included in the trial.</li> <li>2) Subject on Pioglitazone should be included in the study after 3 months of discontinuation of Pioglitazone.</li> </ol> <p>Hence, the firm is required to submit the India specific protocol addendum to the CDSCO.</p> |
| 14.  | CT/01/19<br>Online submission<br>(11652)<br>Semaglutide | M/s. Novo-<br>Nordisk | <p>The firm presented the proposed protocol amendment to Version 4.0 (Amendment 3.0) dated 03FEB2021 under the study protocol no. NN9535-4352 before the committee.</p> <p>After detailed deliberation, the committee recommended the approval of the</p>  |

| S.No                  | File Name & Drug Name, Strength   | Firm Name   | Recommendations  |
|-----------------------|---|---|--|
|                       |   |   | proposed protocol amendment as presented.  |
| <b>BA/BE Division</b> |   |   |  |
| 15.                   | 12-09/2021/BA-BE/Misc-23/DC<br>Levothyroxine Sodium Intranasal Spray 300mcg/ dose | M/s. Admerus Biosciences Private Limited, Telangana- 501401 | The firm presented the BE study protocol before the committee.<br><br>After detailed deliberation, the committee recommended to conduct some animal studies for pharmacokinetics & safety data and submit to CDSCO for further review. |